All In Biotech

Drug Trial Radar · NCT03252340

Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Observational Study to Evaluate the Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Feb 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

11

Actual

Start

Sep 19, 2017

Primary completion

Aug 17, 2022

Study completion Sep 27, 2022

Sponsor

Lead sponsor
EHL Bio Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 17, 2017

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate safety in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of ADSTEM Inj. Since this is an observational study of patients participated in Phase 1 clinical trials, no drug is administered in this study.

Conditions

  • Atopic Dermatitis

Interventions

  • ADSTEM Inj.Drug

    1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial. 2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tumor formationTime frame: 60months after treatment of ADSTEM Inj.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chungnam National University Hospital

    Daejeon, Chungcheongnam-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.